<DOC>
	<DOCNO>NCT01951599</DOCNO>
	<brief_summary>To determine relative bioavailability different oral formulation AZD9291 effect food healthy volunteer .</brief_summary>
	<brief_title>To Determine Relative Bioavailability Different Formulations AZD9291 Effect Food .</brief_title>
	<detailed_description>A Phase I , Open-label , Single-center , Sequential Design Study Healthy Volunteers Determine Relative Bioavailability Different Oral Formulations AZD9291 Effect Food</detailed_description>
	<mesh_term>Osimertinib</mesh_term>
	<criteria>1 , Body mass index 19 30 kg/m2 weight least 50 kg 100 kg . 2 , Volunteers must willing use condom , unless partner postmenopausal , surgically sterile , use effective hormonal method contraception intrauterine coil . 3 . In addition , volunteer must agree continue take similar contraceptive precaution 4 month last dose AZD9291 . 1 . Any clinically relevant abnormality physical examination , vital sign , hematology , clinical chemistry , urinalysis ECG baseline opinion Investigator . 2 . Volunteers receive live liveattenuated vaccine 2 week prior dose . 3 . History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge Investigator , history hypersensitivity AZD9291 , excipients , drug similar chemical structure class .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase I , healthy , bioavailability , pharmacokinetics , safety , tolerability .</keyword>
</DOC>